Filing Details
- Accession Number:
- 0000899243-20-021031
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-03 19:10:53
- Reporting Period:
- 2020-07-30
- Accepted Time:
- 2020-08-03 19:10:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1340652 | Chemocentryx Inc. | CCXI | Pharmaceutical Preparations (2834) | 943254365 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1416422 | Ltd. Pharma Vifor | Rechenstrasse 37 Ch-9014 St. Gallen V8 | No | No | Yes | No | |
1675217 | Ltd (International) Vifor | Rechenstrasse 37 Ch-9014 St. Gallen V8 | No | No | Yes | No | |
1757924 | Ltd. Pharma Renal Care Medical Fresenius Vifor | Rechenstrasse 37 Ch-9014 St. Gallen V8 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-30 | 1,156 | $53.37 | 9,330,670 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-30 | 24,458 | $54.43 | 9,306,212 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-30 | 22,467 | $54.85 | 9,283,745 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-31 | 10,009 | $51.74 | 9,273,736 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-31 | 29,699 | $52.57 | 9,244,037 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-07-31 | 694 | $54.33 | 9,243,343 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-08-03 | 785 | $52.92 | 9,242,558 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-08-03 | 31,823 | $53.62 | 9,210,735 | No | 4 | S | Indirect | See Footnotes |
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-08-03 | 16,650 | $54.58 | 9,194,085 | No | 4 | S | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
Footnotes
- In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
- Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 5,860,752 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
- Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $53.60, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.64 to $55.34, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.15 to $52.14, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.17 to $53.02, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.00, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.27 to $53.24, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.28 to $54.18, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.32 to $54.81, inclusive.